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The anticancer activity of disulﬁram (DS) is copper(II) (Cu)-depen-
dent. This study investigated the anticancer mechanisms of DS/Cu
using in vitro cytotoxicity and metabolic kinetic analysis. Our study
indicates that DS/Cu targets cancer cells by the combination of
two types of actions: (1) instant killing executed by DS/Cu reaction
generated reactive oxygen species; (2) delayed cytotoxicity intro-
duced by the end product, DDC-Cu. Nanoencapsulation of DS
might shed light on repositioning of DS into cancer treatment.
Introduction
Disulfiram (DS), an anti-alcoholism drug used in clinic for
over 60 years,1 demonstrates excellent in vitro anticancer
activity in a wide range of cancer cell lines.2–11 The potential
molecular anticancer mechanisms of DS include inhibition of
proteasome/NFκB pathway,3,12 MDR1,13 topoisomerase and
MMP.14 DS is also an irreversible aldehyde dehydrogenase
(ALDH) inhibitor targeting cancer stem cells.7–9,11 The in vitro
cytotoxicity of DS is entirely dependent on supplement of
copper(II) (Cu) or some other transition bivalent metal ions in
the culture medium.2,6,7,15–17 Cu plays a crucial role in redox
reactions and triggers generation of reactive oxygen species
(ROS), which damage DNA, protein and lipids leading cells
into apoptosis. Although the concept of using Cu to tackle
cancer was proposed many decades ago,18 it has never
demonstrated clinical anticancer eﬃcacy. This is partially due
to the strict control of Cu transport into cancer cells by
the trans-membrane Cu transporter Ctr1.3 Diethyldithio-
carbomate (DDC), the derivative of DS, chelates copper to form
a DDC-Cu complex and transports Cu into cancer cells.2,11
Supplementing with Cu, DS is highly toxic to cancer cells in
vitro.2,6,7,15–17
Although prompted by the very promising lab data, several
clinical trials using oral version of DS plus copper gluconate
in cancer treatment have been completed or on-going
(https://clinicaltrials.gov/ct2/results?term=disulfiram+AND+
cancer&Search=Search), no positive data have been published.
Therefore, elucidating the discord between the anticancer
activity of DS in laboratory and clinic is of significant clinical
importance. Recently it was suggested that the in vitro cytotoxi-
city of DS in cancer cells is introduced by ROS generated from
the reaction of DDC and Cu rather than the final product,
DDC-Cu. The detail of the ROS generated from DDC and Cu
reaction is presented in the Scheme 2 of Lewis’ recent publi-
cation.19 DS and Cu may not be able to react near the cancer
cells in vivo. Considering the extremely short half-life of ROS,20
it may be impossible to translate the in vitro cytotoxic eﬀect of
DS into clinic. The present study intends to answer a very
serious challenge: if DS can be repositioned into cancer
indication?
Results and discussion
Firstly, we set up an in vitro assay to compare the cytotoxicity
of DDC-Cu and DS plus Cu (DS/Cu). If the cytotoxicity of DS in
cancer cell is only introduced by the DS/Cu reaction, the
DDC-Cu should not show significant cytotoxicity. The MCF7
breast cancer cells (5 × 103 per well) were cultured in 96-well
plates and then subjected to the treatment of DS/Cu [equal
molar ratio of DS (Sigma, Dorset, UK; in DMSO) and CuCl2
(in H2O)] or DDC-Cu (TCI, Merseyside, UK; in DMSO).
After 72 hours exposure, the cells were subjected to a typical
in vitro MTT assay.21 In contrast to our original hypothesis,
both DDC-Cu and DS/Cu are highly cytotoxic to MCF7 cells
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(Fig. 1A and B). In comparison with DS/Cu (IC50: 449 nM),
DDC-Cu is even more cytotoxic (IC50: 238.7 nM, p < 0.01). Our
finding indicates that the cytotoxicity of DS/Cu is not solely
caused by the reaction of DS and Cu. DDC-Cu, the final
product of the reaction, may play more important role in DS/
Cu induced cell death.
To determine the time-dependent cytotoxicity of DS/Cu
reaction and DDC-Cu, we performed the following experi-
ments. The cancer cells were plated on 96-well plates and
exposed to DDC-Cu or DS/CuCl2 (1 : 1 molar ratio). After 30, 60,
180 and 360 min drug exposure, the cells were cultured for
another 72 hours in drug-free medium and subjected to MTT
assay. The massive cell death was observed after 30 min
exposure to DS/Cu and further killing was detected until
180 min exposure (Fig. 1C and D). This is highly in line with
the UV-Vis absorption time-course plot of DS/Cu reaction pre-
viously published.19 No significant cell killing was observed
within 30 min exposure to DDC-Cu but markedly intensified
after 180 min exposure (Fig. 1C and D).
ROS is a group of reactive oxygen-containing chemical
species, including the superoxide anion (O2
−), hydrogen per-
oxide (H2O2) and the hydroxyl radical (HO
•), which is biologi-
cally generated from the mitochondrial respiratory chain
reaction in living cells. The half-life of ROS is only 10−9 s (HO•)
to 1 ms (H2O2).
20 When equal molar ratio of DS and Cu are
mixed, the reaction is instantly triggered and completed
within 150 min.19 Therefore, if the cytotoxicity is induced by
the extracellular ROS generated from DS/Cu reaction, the cyto-
toxic eﬀect should be observed instantly after drug exposure.
Further more, we examine the ROS generation from DS/Cu
reaction (Fig. 2). Equal molar concentration (10 μM or 10 mM)
of DS and CuCl2 was mixed in culture medium. The ROS gen-
erated in the system was detected by OxyBURST H2HFF Green
Assay (Invitrogen, Paisley, UK) following the supplier’s instruc-
tion. High levels of ROS were detected in DS/Cu medium. At
working concentration (10 μM), DS/Cu generated significantly
higher ROS than those from 18.5 μM H2O2 and was maximised
within 4 hours. Lower levels of ROS were detected in 10 mM
DS/Cu reaction which may be due to the instant crystallization
of DS and Cu at higher concentration. No ROS was detected in
the DDC-Cu containing medium.
Furthermore, we examined the metabolic kinetics of DS/Cu
and DDC-Cu in cell culture. MCF7 cells were treated with
equal molar ratio of DS and CuCl2 at a final concentration of
2 μM. The medium and cells were separately collected after 30,
180 and 360 min. The reaction products of DS/Cu in the whole
cell lysate and medium were extracted in 0.25 ml chloroform
and subjected to HPLC analysis. The separation was achieved
using a C18 reverse-phase column at an injection volume of
20 μl and a flow rate of 1 ml min−1. The wave length of 435 nm
and 275 nm, mobile phase of 10 : 90% and 30 : 70% (water :
methanol, v/v) were used for DDC-Cu and DS analysis
respectively.
The pure standard DDC-Cu and DS were detected at reten-
tion time of 4.15 and 7.07 min respectively (Fig. 3A). The
DDC-Cu was detected in both medium and cell lysate extracts
after culturing in DS/Cu-containing medium for 30 min. The
peak was steadily increased in the medium and cell lysate over
360 min (Fig. 3B and C). The stable levels of DDC-Cu were
detected in the medium and cell lysate when pure DDC-Cu
compound was added into the cell culture (Fig. 3B and C). DS
was detected in the DS/Cu cultured medium at 30 min and
sharply dropped to undetectable level (Fig. 3C). No DS was
detected in the cell lysate. These results indicate that DS/Cu
reaction generated DDC-Cu can penetrate into and cumulate
within cancer cells (Fig. 3B) to induce apoptosis.
The findings from this study suggest that the cytotoxicity of
DS/Cu may be introduced from the following two actions. (1)
DS/Cu reaction-generated ROS: This is an instant and short-
Fig. 1 Cytotoxicity of DS/Cu and DDC-Cu on MCF7 cells. A and B. After
72 h exposure, DDC-Cu showed higher cytotoxicity to cancer cells. C
and D. In comparison with DDC-Cu, DS/Cu demonstrated earlier killing
eﬀect. Inserted ﬁgures in A and C: IC50s; **p < 0.01.
Fig. 2 The ROS activity detected in DS/Cu, DDC-Cu and H2O2 contain-
ing cell culture medium. The strength of ﬂuorescence represents the
intensity of ROS in the medium.
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term action; (2) toxic eﬀect of DDC-Cu: DDC-Cu is an end
product with delayed but stronger long-lasting eﬀect. The che-
lation of DS with Cu is indispensible for both of these two
actions. Scheme 1 shows the metabolic pathways of DS. In vivo,
DS is instantly reduced to DDC in the bloodstream, which is
also very unstable and promptly converted into the irreversible
downstream metabolites, e.g. DDC-glucuronide, methylated
DDC and other degraded products. In all of these products,
the functional sulfhydryl group of DDC is destroyed making
DDC lose its chelating ability. Our unpublished data show that
DS is undetectable after mixed with horse serum for 2 min.
Due to the very short half-life of DS and DDC in the blood-
stream, no ROS and DDC-Cu will be generated if the oral
version of DS and Cu is administered to patient separately.
This may explain the discrepancy between in vitro experiment
and clinic. To resolve this problem, we recently protected DS
from degradation in the bloodstream by encapsulation of DS
into nanoparticles. This strategy significantly extended the
half-life of DS. We have demonstrated that in combination
with oral administration of copper gluconate, intravenous
version of nanoencapsulated DS showed significantly stronger
anticancer eﬃcacy in mouse breast, lung and brain cancer
xenograft models (ref. 9 and unpublished data). Therefore,
nanomedicine may be a novel strategy for translation of
DS into cancer indication. In contrast to DS, DDC-Cu is a very
stable chemical with a half-life in serum for more than
4 hours (our unpublished data). It can potentially be another
druggable candidate for cancer therapeutics.
Conclusion
Our results demonstrate that DS/Cu induces cell death via
instant and delayed phases. The instant phase may be solely
caused by the DS/Cu reaction generated ROS. The delayed
phase may follow the rule of conventional anticancer drugs,
which may interfere the vital molecular pathways within the
cancer cells and induce apoptosis. Although the reaction-
induced cytotoxicity was started earlier, DDC-Cu showed sig-
nificantly stronger anticancer activity after 2 to 3 doubling
time.
We acknowledge support from the Tertiary Education Trust
Fund Niger Delta University, Nigeria for PET’s PhD student-
ship and Marie-Curie IIF Program (PIIF-GA-2013-629478)
for ZPW.
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